Aethlon Medical (AEMD) Proxy Filing summary

Executive summary

• The annual meeting will be held virtually on February 19, 2026, with full participation rights for shareholders.

• Key clinical progress includes completion of the first cohort in an oncology trial in Australia, with no serious adverse events and DSMB approval to advance to the next cohort.

• The company resolved Nasdaq compliance issues in 2025 and remains listed on the Nasdaq Capital Market.

• The clinical study focuses on safety and dose-finding for Hemopurifier treatments in solid tumor patients unresponsive to PD-1 therapy, with exploratory endpoints on immune response and extracellular vesicle reduction.

Voting matters and shareholder proposals

• Shareholders will vote on electing five directors, ratifying the independent auditor, amending the equity incentive plan, increasing authorized shares, approving PIPE and inducement warrant issuances, and potential adjournment.

• Board recommends voting “FOR” all proposals and nominees.

• Proposals include increasing authorized common stock from 6,000,000 to 100,000,000 shares and approving up to 2,031,024 shares for warrant exercises related to recent financings.

Board of directors and corporate governance

• The board consists of five members, four of whom are independent under Nasdaq rules.

• Board committees include Audit, Compensation, and Nominating and Corporate Governance, with clear independence and chair assignments.

• The company maintains a Code of Business Conduct and Ethics and anti-hedging/pledging policies.

• All directors attended at least 75% of meetings in FY2025.